286 related articles for article (PubMed ID: 28217821)
1. Physicians' Experiences as Patients with Statin Side Effects: A Case Series.
Koslik HJ; Meskimen AH; Golomb BA
Drug Saf Case Rep; 2017 Dec; 4(1):3. PubMed ID: 28217821
[TBL] [Abstract][Full Text] [Related]
2. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series.
Cham S; Koslik HJ; Golomb BA
Drug Saf Case Rep; 2016 Dec; 3(1):1. PubMed ID: 27747681
[TBL] [Abstract][Full Text] [Related]
3. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
[TBL] [Abstract][Full Text] [Related]
4. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
5. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
6. Statin-associated muscle-related adverse effects: a case series of 354 patients.
Cham S; Evans MA; Denenberg JO; Golomb BA
Pharmacotherapy; 2010 Jun; 30(6):541-53. PubMed ID: 20500044
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
Moriarty PM; Jacobson TA; Bruckert E; Thompson PD; Guyton JR; Baccara-Dinet MT; Gipe D
J Clin Lipidol; 2014; 8(6):554-561. PubMed ID: 25499937
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Gagné C; Gaudet D; Bruckert E;
Circulation; 2002 May; 105(21):2469-75. PubMed ID: 12034651
[TBL] [Abstract][Full Text] [Related]
9. Statin-related adverse events: a meta-analysis.
Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
11. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.
Golomb BA; McGraw JJ; Evans MA; Dimsdale JE
Drug Saf; 2007; 30(8):669-75. PubMed ID: 17696579
[TBL] [Abstract][Full Text] [Related]
12. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
13. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Tungsubutra W; Phongtuntakul B
J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.
Indumathi C; Anusha N; Vinod KV; Santhosh S; Dkhar SA
J Clin Diagn Res; 2017 Jul; 11(7):FC01-FC05. PubMed ID: 28892923
[TBL] [Abstract][Full Text] [Related]
15. Statin related adverse effects and patient education: a study from resource limited settings.
Mulchandani R; Lyngdoh T; Chakraborty P; Kakkar AK
Acta Cardiol; 2018 Aug; 73(4):393-401. PubMed ID: 29179650
[TBL] [Abstract][Full Text] [Related]
16. Striated muscle safety of ezetimibe/simvastatin (Vytorin).
Davidson MH; Maccubbin D; Stepanavage M; Strony J; Musliner T
Am J Cardiol; 2006 Jan; 97(2):223-8. PubMed ID: 16442367
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.
Siriangkhawut M; Tansakul P; Uchaipichat V
Saudi Pharm J; 2017 Sep; 25(6):823-829. PubMed ID: 28951665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF
J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
